Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Summary

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.

Timeline

Start

2024-07-25

Primary completion

2026-12-01

Completion

2027-07-01

Drugs

Indications